Interferon-α2b, with or without Prior Hepatic Artery Embolization: Clinical Response and Survival in Mid-Gut Carcinoid Patients: The Norwegian Carcinoid Study

References

• Wilander E, Lundquist E, Öberg K. Gastrointestinal carcinoid tumours. Progr Histochem Cytochem 1989; 19: 1–88
   PubMedGoogle Scholar
• Ahlman H, Wangberg B, Jansson S, Stenqvist O, Geterud K, Tylen U, et al. Management of disseminated midgut carcinoid tumours. Digestion 1991; 49: 78–96
   PubMed Web of Science ®Google Scholar
• McEntee GP., Nargorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumours. Surgery 1990; 108: 1091–6
   PubMed Web of Science ®Google Scholar
• Moertel C G, Sauer W, Dockerty M B, Baggenstoss AH. Life history of the carcinoid tumour of the small intestine. Cancer 1961; 14: 901–12
   PubMed Web of Science ®Google Scholar
• Moertel CG. An odyssey in the land of small tumours. J Clin Oncd 1987; 5: 1503–22
   Web of Science ®Google Scholar
• Søreide O, Berstad T, Bakka A, Schrumpf E, Hanssen L E, Engh V, et al. Surgical treatment as a principle in patients with advanced carcinoid turnours. Surgery 1992; 111: 48–54
   PubMed Web of Science ®Google Scholar
• Kolmannskog F, Kolbenstvedt A N, Schrumpf E, Hanssen LE. Side effects and complications following hepatic artery embolization in carcinoid syndrome. Scand J Gastroenterol 1991; 26: 557–62
   PubMed Web of Science ®Google Scholar
• Markowitz JO. The hepatic artery. Surg Gynecol Obstet 1952; 95: 644–6
   PubMedGoogle Scholar
• Aune S, Schistad G. Carcinoid liver metastases treated with hepatic dearterialization. Ann J Surg 1972; 123: 715–7
   PubMed Web of Science ®Google Scholar
• Brtensson M H, Nobin A, Bengmark S, Lunderquist A, Owman T, Sanden G. Embolization of the liver in the management of metastatic carcinoid tumours. J Surg Oncol 1984; 27: 152–8
   PubMedGoogle Scholar
• Geterud K, Tylen U, Jansson S, Stenquist O, Tisell L E, Ahlmann H. Hepatic artery embolization in the treatment of the midgut carcinoid syndrome and other advanced endocrine tumours metastatic to the liver. J Intervent Radiol 1990; 5: 69–76
   Google Scholar
• Coupe M O, Hodgson H JF, Hemingway A, Allison DJ. Effect of hepatic artery embolization on survival in the carcinoid syndrome. J Interv Radiol 1989; 4: 179–81
   Google Scholar
• Mitty H A, Warner R RP, Newman L H, Train J S, Parnes IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985; 155: 623–6
   PubMed Web of Science ®Google Scholar
• Borden E C, Sondel PM. Lymphokines and cytokines as cancer treatment. Cancer 1990; 65: 800–14
   PubMed Web of Science ®Google Scholar
• Valimaki M, Järvinen H, Salmela P, Sjoblom S M, Peeleenen R. Is the treatment of metastatic carcinoids tumours with interferon not as successful as suggested?. Cancer 1991; 67: 547–9
   PubMed Web of Science ®Google Scholar
• Öberg K, Norheim I, Lind E, Alm G, Lundqvist G, Wide L, et al. Treatment of malignant carcinoid tumours with human leucocyte interferon. Cancer Treat Rep 1986; 70: 1297–304
   PubMedGoogle Scholar
• Moertel C G, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumour and the malignant carcinoid syndrome with recom-binant leucocyte A interferon. J Clin Oncol 1989; 7: 865–8
   PubMed Web of Science ®Google Scholar
• Öberg K, Funa K, Alm G. Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumours and the carcinoid syndrome. N Engl J Med 1983; 309: 129–33
   PubMed Web of Science ®Google Scholar
• Hadju S I, Winawer S J, Myers W PL. Carcinoid tumours. A study of 204 cases. AJCP 1974; 61: 521–7
   Google Scholar
• Norheim I, Öberg K, Theodorsson-Norheim E, Lindgren P G, Lundqvist G, Magnusson A, et al. Malignant carcinoid tumours. An analysis of 103 patients with regard to tumour localization, hormone production, and survival. Ann Surg 1987; 206: 115–25
   PubMed Web of Science ®Google Scholar
• Hanssen L E, Schrumpf E, Kolbenstvedt A N, Tausje J, Dolva LO. Treatment of malignant metastatic midgut carcinoid tumours with recombinant human a 2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989; 24: 787–95
   PubMed Web of Science ®Google Scholar
• Roldan C A, Shively B K, Lau CC., Gurule IT, Smith EA, Crawford MH. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospho-lipid antibodies. J Am Coll Cardiol 1992; 90: 1127–34
   Google Scholar
• Ahlman H, Ahlund L, Dahlstrom A, Skolnik O., Nilsson G, Tisell L-E, et al. Use of a somatostatin analogue in association with surgery and hepatic arterial embolization'in the treatment of the carcinoid syndrome. Br J Cancer 1987; 56: 840–2
   PubMed Web of Science ®Google Scholar
• Öberg K, Eriksson B. Medical treatment of neuroendocrine tumours of the gut and pancreatic tumours. Acta Oncol 1989; 28: 425–31
   PubMed Web of Science ®Google Scholar
• Lundin L, Norheim I, Landelius J, Öberg K, Theodorsson-Norheim E. Carcinoid heart disease. Relationship of circulating substances to ultrasound detectable cardiac abnormalities. Circulation 1988; 77: 264–9
   PubMed Web of Science ®Google Scholar
• Andersson T, Wilander E, Eriksson B, Lingren P G, Oherg K. Effects of interferon on tissue content in liver metastases of human carcinoid tumours. Cancer Res 1990; 50: 3413–5
   PubMed Web of Science ®Google Scholar
• Ozaki Y, Edelstein M P, Duch DS. The actions of interferon and antiinflammatory agents on induction of indoleamine-2.3–dioxygenase in human peripheral blood monocytes. Biochem Biophys Res Commun 1987; 144: 1147–53
   PubMed Web of Science ®Google Scholar
• Taylor MW. Relationship between interferon-gamma, indolea-mine-2′,3′-dioxygenase and tryptophan catabolism. FASEB J 1991; 5: 2516–22
   PubMed Web of Science ®Google Scholar
• Bocci V. Evaluations of routes of administration of interferon in cancer. A review and a proposal. Cancer Drug Deliv 1984; 1: 313–6
   Google Scholar
• Dianzani F. Biological basis for the clinical use of interferon. Gut 1993; 74–6, Suppl
   Google Scholar
• Ronnblom L E, Alm G, Öberg K. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumours. Ann Intern Med 1991; 115: 178–83
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J, Shearer M, Rozengurt E. Inhibitory effects of interferon on cellular Dna-synthesis; modulation by mitogenic factors. J lnterfer Res 1981; 1: 401–9
   PubMedGoogle Scholar
• Wilander E, Bengtsson A, Norhcim I, Öberg K. Interferon-induced nuclear DNA alterations in malignant carcinoid tumours in vivo. JNCI 1986; 76: 429–33
   PubMed Web of Science ®Google Scholar
• Chuang V P, Wallace S. Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 1981; 140: 51–8
   PubMed Web of Science ®Google Scholar
• Doppman JI., Girton M, Kahn RE. Proximal versus peripherial hepatic embolization: experimental study in monkeys. Radiology 1978; 128: 577–88
   PubMedGoogle Scholar
• Torristi J, Berg C, Bonnem E, Dritschilo A. The combined use of interferon and radiotherapy in cancer management. Semin Oncol 1986; 3: 78–83, Suppl 2
   Google Scholar
• Oken MM. Kyle RA. Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma. Semin Oncol 1991; 18: 30–2, Suppl 7
   PubMedGoogle Scholar